The effectiveness of tiletamine-zolazepam (1.7 mg/kg) plus medetomidine (0.07 mg/kg; TZM) as an immobilizing combination in raccoons (Procyon lotor; n=43) and striped skunks (Mephitis mephitis; n=7) was evaluated during October 2019. Mean (±SD) induction time for raccoons was 15.0±6.6 min. First signs of recovery (head up) occurred 12.9±6.0 min after receiving atipamezole reversal (0.35 mg/kg) and animals were standing in 30.3±16.1 min. Mean induction time for skunks was 11.7±5.8 min. Following reversal, skunks first raised their heads in 6.7±4.3 min and stood in 17.1±12.9 min. Recovery in skunks and female raccoons was not related to length of time immobilized, but male raccoons that were immobilized for longer periods of time stood faster after reversal. Raccoon heart rate (HR) remained steady during immobilization, but respiration rate (RR) and rectal temperature (RT) declined. The HR and RR were similar among males and females, but RT of male raccoons were, on average, 0.5 C higher than those of females, and rate of temperature decline was slower for males. The HR, RR, and RT of skunks declined during immobilization. Although induction times for both raccoons and skunks were longer than expected, induction and recovery were smooth, side effects were few, analgesia was adequate for nonsurgical procedures, and reversal reduced time in captivity.
You have requested a machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Neither BioOne nor the owners and publishers of the content make, and they explicitly disclaim, any express or implied representations or warranties of any kind, including, without limitation, representations and warranties as to the functionality of the translation feature or the accuracy or completeness of the translations.
Translations are not retained in our system. Your use of this feature and the translations is subject to all use restrictions contained in the Terms and Conditions of Use of the BioOne website.
Vol. 58 • No. 4